Published in Obesity and Diabetes Week, September 8th, 2003
"Orlistat has been well studied in several populations, including patients who do and do not have type 2 diabetes and patients who have impaired glucose tolerance. Overall, modest, but significant, weight loss was seen in all three groups of patients with favorable effects on the comorbidities of obesity. Orlistat has not been associated with a serious adverse event profile, and the mild gastrointestinal effects that are seen in some patients are well tolerated," an investigator in the United States reports.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.